Career as Executive - Training & Development (Hospital Pharmacies) at Apollo Hospitals
Apollo Hospitals is the forerunner of integrated healthcare in Asia, as well as globally. The group's futuristic vision has ensured that it has been in a position of strength at every touch point of the healthcare delivery chain. Its presence encompasses across 56 hospitals, more than 2300 pharmacies, over 100 primary care & diagnostic clinics, 115 telemedicine units across 9 countries, health insurance services, global projects consultancy, 15 academic institutions and a Research Foundation with a focus on global clinical trials, epidemiological studies, stem-cell and genetic research.
Over the past three decades Apollo Hospitals' transformative journey has forged a legacy of excellence in Indian healthcare. The Group has continuously set the agenda and led by example in the blossoming private healthcare space. One of Apollo's significant contributions has been the adoption of clinical excellence as an industry standard. Apollo pioneered the concept - the group was the first to invest in the pre-requisites that led to international quality accreditation like the JCI and also developed centers of excellence in Cardiac Sciences, Orthopedics, Neurosciences, Emergency Care, Cancer and Organ Transplantation. Along with excellence the Apollo philosophy rests on the pillars of technological superiority, a warm patent- centric approach, a clear and distinct cost advantage and a edge in forward-looking research. Apollo's spectacular success rests on sustained commitment and investments in each of these pillars.
Post: Executive - Training & Development (Hospital Pharmacies) - 2 posts
Fresenius Kabi Oncology Limited is a public listed company primarily operating in the field of Research & Development and manufacturing of world-class oncology drugs. The company strives to provide most advanced third generation chemotherapeutic drugs right from development to manufacturing & marketing across the globe. It is fast emerging as a leading player in oncology generics on the strength of its comprehensive product portfolio of injectables, oral cytotoxics, cytostatics, intermediates and active pharmaceutical ingredients (APIs).
